We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRTU
151
DELISTED
Virtusa Corporation
VRTU
| $26.3M | 0.05% |
592,233
+3,591
| +0.6% | +$175K |
|
152
Post Holdings
POST
$4.09B
| $26.2M | 0.05% |
384,381
+14,500
| +4% | +$1.02M |
|
153
Armstrong World Industries
AWI
$7.78B
| $26.1M | 0.05% |
268,196
-32,299
| -11% | -$2.89M |
|
154
ICF International
ICFI
$1.54B
| $26.1M | 0.05% |
357,823
+62,639
| +21% | +$4.69M |
|
155
Home BancShares
HOMB
$6.18B
| $25.7M | 0.05% |
1,334,019
-99,328
| -7% | -$1.85M |
|
156
NMI Holdings
NMIH
$3.31B
| $25.6M | 0.05% |
900,817
+395,036
| +78% | +$11M |
|
|
TMX
157
DELISTED
Terminix Global Holdings, Inc.
TMX
| $25.3M | 0.05% |
485,495
-18,456
| -4% | -$950K |
|
158
Steven Madden
SHOO
$3.53B
| $25.3M | 0.05% |
744,530
+36,726
| +5% | +$1.21M |
|
159
Globant
GLOB
$1.61B
| $25.2M | 0.05% |
249,169
-36,519
| -13% | -$3.18M |
|
160
IMAX
IMAX
$2.73B
| $24.9M | 0.05% |
1,234,174
+130,253
| +12% | +$2.94M |
|
161
NeoGenomics
NEO
$2B
| $24.9M | 0.05% |
1,134,242
+55,542
| +5% | +$1.22M |
|
162
Prosperity Bancshares
PB
$8.88B
| $24.9M | 0.05% |
376,614
-26,089
| -6% | -$1.81M |
|
163
Americold
COLD
$4.11B
| $24.7M | 0.05% |
762,134
+169,753
| +29% | +$5.38M |
|
164
Rogers Corp
ROG
$2.39B
| $24.3M | 0.05% |
140,820
+106,090
| +305% | +$17.3M |
|
165
Repligen
RGEN
$9B
| $24.3M | 0.05% |
+282,739
| New | +$19.3M |
|
166
HEICO Corp
HEI
$50.8B
| $24.2M | 0.05% |
180,957
-40,580
| -18% | -$4.51M |
|
|
CONE
167
DELISTED
CyrusOne Inc Common Stock
CONE
| $24.1M | 0.05% |
418,172
-38,888
| -9% | -$2.28M |
|
168
Advanced Energy
AEIS
$13B
| $24M | 0.04% |
426,041
+44,657
| +12% | +$2.39M |
|
|
PRMW
169
DELISTED
Primo Water Corporation
PRMW
| $23.7M | 0.04% |
1,777,727
-130,236
| -7% | -$1.83M |
|
|
GHDX
170
DELISTED
Genomic Health, Inc.
GHDX
| $23.2M | 0.04% |
399,482
+19,583
| +5% | +$1.16M |
|
171
HDFC Bank
HDB
$122B
| $23.2M | 0.04% |
713,116
+60,496
| +9% | +$1.82M |
|
|
GRA
172
DELISTED
W.R. Grace & Co.
GRA
| $23.2M | 0.04% |
304,522
-11,401
| -4% | -$854K |
|
173
AMN Healthcare
AMN
$1.19B
| $23.1M | 0.04% |
425,828
+50,907
| +14% | +$2.58M |
|
174
Chefs' Warehouse
CHEF
$4.45B
| $23M | 0.04% |
655,941
-22
| -0% | -$724 |
|
|
ALE
175
DELISTED
Allete
ALE
| $22.8M | 0.04% |
274,211
-16,121
| -6% | -$1.33M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.